Pulmonary Hypertension Care Centers: Hope for the Future From a Patient's and Caregiver's Perspectives

2015 ◽  
Vol 13 (4) ◽  
pp. 172-173
Author(s):  
Diane Ramirez ◽  
Laura Hoyt D'Anna

In 1987, after three years of being treated aggressively for asthma and then a prolapsed mitral valve, I was finally diagnosed with primary pulmonary hypertension (PPH). I was told I would be lucky if I lived 2 years without having a heart/double lung transplant and that I didn't have much time to get my affairs in order. There were fewer than 200 patients in the United States at the time. There were no treatment centers, support groups, or even an advocacy group like the Pulmonary Hypertension Association (PHA). I struggled with the loneliness of this diagnosis and the lack of information available.

1999 ◽  
Vol 123 (6) ◽  
pp. 539-540 ◽  
Author(s):  
Jennifer Strother ◽  
Peter Fedullo ◽  
Eunhee S. Yi ◽  
Eliezer Masliah

Abstract Anorectic agents, such as aminorex and fenfluramine derivatives, have been associated previously with the development of primary pulmonary hypertension. The combination diet drug phentermine-fenfluramine (or “phen-fen”) was recently marketed in the United States. We describe a case of a 39-year-old woman with rapidly progressing, fatal pulmonary hypertension following administration of phentermine-fenfluramine. Autopsy was remarkable for complex pulmonary vascular lesions most consistent with thrombotic arteriopathy.


2011 ◽  
Vol 141 (3) ◽  
pp. 828-832.e1 ◽  
Author(s):  
Farhan Zafar ◽  
Jeffrey S. Heinle ◽  
Marc G. Schecter ◽  
Joseph W. Rossano ◽  
George B. Mallory ◽  
...  

2011 ◽  
Vol 91 (11) ◽  
pp. 1293-1296 ◽  
Author(s):  
Tse-Ling Fong ◽  
Yong W. Cho ◽  
Linda Hou ◽  
Ian V. Hutchinson ◽  
Richard G. Barbers ◽  
...  

2010 ◽  
Vol 89 (6) ◽  
pp. 639-643 ◽  
Author(s):  
John E. Scarborough ◽  
Kyla M. Bennett ◽  
Robert D. Davis ◽  
Shu S. Lin ◽  
Elizabeth T. Tracy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document